These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 15784032

  • 1. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial.
    Bahrami H, Daryani NE, Haghpanah B, Moayyeri A, Moghadam KF, Mirmomen S, Kamangar F.
    Am J Gastroenterol; 2005 Apr; 100(4):856-61. PubMed ID: 15784032
    [Abstract] [Full Text] [Related]

  • 2. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M, Mutlu B, Erdoğan S, Meriç M, Willke A.
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [Abstract] [Full Text] [Related]

  • 3. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
    Yao G, Wang B, Cui Z, Yao J, Zeng M.
    Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
    [Abstract] [Full Text] [Related]

  • 4. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL, Wang H, Niu J, Chim AM, Sung JJ.
    Antivir Ther; 2007 May; 12(3):345-53. PubMed ID: 17591024
    [Abstract] [Full Text] [Related]

  • 5. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, Sharma BC.
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: clinical significance and correlation with serological markers.
    Yalçin K, Değertekin H, Alp MN, Tekeş S, Satici O, Budak T.
    Turk J Gastroenterol; 2003 Sep; 14(3):157-63. PubMed ID: 14655057
    [Abstract] [Full Text] [Related]

  • 8. Chronic carriers of hepatitis B virus in Bangladesh: a comparative analysis of HBV-DNA, HBeAg/anti-HBe, and liver function tests.
    Hasan KN, Rumi MA, Hasanat MA, Azam MG, Ahmed S, Salam MA, Islam LN, Hassan MS.
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):110-7. PubMed ID: 12118438
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications.
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL.
    Hepatology; 2001 Jul; 34(1):139-45. PubMed ID: 11431745
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Natural history of chronic HBV infection: a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project).
    Zacharakis GH, Koskinas J, Kotsiou S, Papoutselis M, Tzara F, Vafeiadis N, Archimandritis AJ, Papoutselis K.
    J Med Virol; 2005 Oct; 77(2):173-9. PubMed ID: 16121378
    [Abstract] [Full Text] [Related]

  • 12. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 13. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC, Yulugkural Z, Vahaboglu H.
    Chemotherapy; 2007 Jul; 53(6):402-6. PubMed ID: 17934260
    [Abstract] [Full Text] [Related]

  • 14. Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss.
    Ferns RB, Naoumov NV, Gilson RJ, Tedder RS.
    J Clin Virol; 2007 Jul; 39(3):199-204. PubMed ID: 17526429
    [Abstract] [Full Text] [Related]

  • 15. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.
    Lian M, Zhou X, Wei L, Qiu S, Zhou T, Li L, Gu X, Luo M, Zheng X.
    Virol J; 2007 Sep 24; 4():93. PubMed ID: 17892580
    [Abstract] [Full Text] [Related]

  • 16. Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection.
    Fischler B, Nyström J, Björnsdottir T, Lindh G, Hultgren C.
    J Pediatr Gastroenterol Nutr; 2007 Jul 24; 45(1):75-83. PubMed ID: 17592368
    [Abstract] [Full Text] [Related]

  • 17. [Follow-up of chronic hepatitis B carriers. Serological course and risk of reactivation].
    Bujanda L, García Bengoechea M, Cilla G, Gil I, yArenas JI.
    Rev Esp Enferm Dig; 1996 May 24; 88(5):335-9. PubMed ID: 8764540
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK.
    Gastroenterology; 2009 Feb 24; 136(2):505-12. PubMed ID: 19101558
    [Abstract] [Full Text] [Related]

  • 19. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.
    Wang XY, Zhang XX, Yao X, Jiang JH, Xie YH, Yuan ZH, Wen YM.
    Vaccine; 2010 Nov 29; 28(51):8169-74. PubMed ID: 20937312
    [Abstract] [Full Text] [Related]

  • 20. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers.
    Kao JH, Chen PJ, Lai MY, Chen DS.
    J Med Virol; 2004 Mar 29; 72(3):363-9. PubMed ID: 14748059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.